

# Central Venous Catheter-related Infections (CRI) in Hematology and Oncology

Recommendations from the society for diagnosis and therapy of haematological and oncological diseases

## **Publisher**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Alexanderplatz 1  
D-10178 Berlin

Executive chairman: Prof. Dr. med. Lorenz Trümper

Phone: +49 (0)30 27 87 60 89 - 0

Fax: +49 (0)30 27 87 60 89 - 18

[info@dgho.de](mailto:info@dgho.de)

[www.dgho.de](http://www.dgho.de)

## **Contact person**

Prof. Dr. med. Bernhard Wörmann  
Medical superintendent

## **Source**

[www.onkopedia-guidelines.info](http://www.onkopedia-guidelines.info)

The information of the DGHO Onkopedia Web Site is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the web site is done so for solely educational purposes. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the DGHO Web Site. This includes any implied warranties and conditions that may be derived from the aforementioned web site information.

# Table of contents

<b>1 Definition and Basic Information .....</b>	<b>2</b>
<b>2 Prevention of Catheter-Related Infections .....</b>	<b>2</b>
<b>3 Diagnosis .....</b>	<b>3</b>
3.1 Diagnostic Criteria .....	3
3.2 Diagnostics .....	3
<b>4 Therapy .....</b>	<b>4</b>
4.1 Antimicrobial Therapy .....	4
4.2 Management of CVC .....	4
<b>5 References .....</b>	<b>5</b>
<b>7 Links .....</b>	<b>5</b>
<b>8 Authors' Affiliations .....</b>	<b>5</b>
<b>9 Disclosure .....</b>	<b>7</b>

# Central Venous Catheter-related Infections (CRI) in Hematology and Oncology

**Date of document:** January 2012

**Compliance rules:**

- [Guideline](#)
- [Conflict of interests](#)

**Authors:** Hans-Heinrich Wolf, Malte Leithäuser, Georg Maschmeyer, Hans-Jürgen Salwender, Ulrike Klein, Iris Chaberny, Florian Weißinger, Dieter Buchheidt, Markus Ruhnke, Gerlinde Egerer, Oliver A. Cornely, Gerd Fätkenheuer, Sabine Mousset

on behalf of the AGIHO Infectious Diseases Working Party of the DGHO

## 1 Definition and Basic Information

Insertion of central venous catheters is a common procedure in the treatment of patients with hematologic malignancies and solid tumors. Catheter-related infections (CRI) cause considerable morbidity. They are also one of the differential diagnoses of fever of unknown origin in neutropenic patients. This guideline on diagnostics and therapy of CRI was developed by the AGIHO Infectious Diseases Working Party of the DGHO.

Categories are based on the evaluation of study results and the recommendations developed by the Infectious Diseases Society of America, ISDA, see [Table 1](#).

**Table 1: Categories of Evidence**

<b>Category, grade Strength of Recommendation</b>	<b>Definition</b>
A	Good evidence to support a recommendation for use
B	Moderate evidence to support a recommendation for use
C	Poor evidence to support a recommendation for use
D	Moderate evidence to support a recommendation against use
E	Good evidence to support a recommendation against use
<b>Quality of Evidence</b>	<b>Definition</b>
I	Evidence from $\geq 1$ properly randomized, controlled trial
II	Evidence from $\geq 1$ well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferable from $> 1$ centre); from multiple time series; or from dramatic results of uncontrolled experiments
III	Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports from expert committees

## 2 Prevention of Catheter-Related Infections

Recommendations are summarized in [Table 2](#).

**Table 2: Prevention of Catheter-Related Infections**

Recommendation	Category of Evidence
Access via the subclavian vein is associated with a lower CRI rate as compared to internal jugular vein	A-I
Compliance with hygiene principles during insertion and standardized aseptic placement help to avoid infections	A-I
Impregnation of CVCs with antiseptics (chlorhexidine/silver sulfadiazine) or antibiotics (minocycline/rifampicin) reduces incidence of catheter colonization	A-I
Education programs for nurses and physicians help to reduce the incidence of CRI	A-II
Ultrasound-guided placement helps to reduce CRI rates	B-I
Alcoholic chlorhexidine solution, alcoholic polyvidone-iodine solutions or 70% propanolol should be used for disinfection of the catheter insertion site	A-I
More frequent replacement does not reduce the incidence of infection	D-I
Systemic prophylactic antibiotic treatment prior to catheter insertion is not recommended	E-I
Topical application of antibiotic ointments for reducing staphylococcal colonization at the catheter insertion site and as a nasal ointment is not recommended	E-I

### 3 Diagnosis

#### 3.1 Diagnostic Criteria

In clinical practice, diagnosis of central venous catheter-related infections is based on symptoms and test results not always withstanding strict definitions. In many cases, CRI can only be presumed backed-up by clinical symptoms and test results listed in [Table 3](#).

**Table 3: Diagnostic Criteria for CRI**

Diagnosis	Criteria
<b>Definite CRI</b>	<ul style="list-style-type: none"> <li>Pathogen detected at the catheter tip by a standard method plus same pathogen with the same susceptibility pattern detected in blood culture</li> </ul> <u>and / or</u> <ul style="list-style-type: none"> <li>DTTP<sup>1</sup> &gt; 2 h</li> </ul> <u>and / or</u> <ul style="list-style-type: none"> <li>CFU Ratio<sup>2</sup> ≥ 10</li> </ul>
<b>Probable CRI</b>	<ul style="list-style-type: none"> <li>Local infection at the insertion site</li> </ul> <u>and / or</u> <ul style="list-style-type: none"> <li>Remission of previously refractory fever within 48h after catheter removal plus positive blood culture</li> </ul> <u>and / or</u> <ul style="list-style-type: none"> <li>Colonization of the catheter tip<sup>3</sup></li> </ul>
<b>Possible CRI</b>	<ul style="list-style-type: none"> <li>Pathogen detected in blood culture that is typically implicated in causing catheter infections (<i>S. epidermidis</i>, <i>S. aureus</i> or other coagulase - negative Staphylococci, <i>Candida</i> spp.)</li> </ul> <u>and / or</u> <ul style="list-style-type: none"> <li>Positive blood culture and no other focus identified in a patient with an indwelling central venous catheter (CVC)</li> </ul>

Legend:

<sup>1</sup> DTTP (Differential Time To Positivity) – Difference in time between positivity of results of catheter culture and peripheral blood culture;

<sup>2</sup> CFU Ratio – Ratio of Colony Forming Units between pathogen detected in quantitative catheter and peripheral blood cultures;

<sup>3</sup> Results above the limit specified for the method

#### 3.2 Diagnostics

Recommendations are summarized in [Table 4](#).

**Table 4: Diagnostics of Central Venous CRIs**

Recommendation	Category of Evidence
One pair of blood cultures (aerobic and anaerobic) to be taken from the catheter and one from a peripheral vein for microbiological evaluation	A-II
DTTP <sup>1</sup> for routine diagnostic purposes	A-I
Semiquantitative culturing for microbiological diagnosis of CRI after catheter removal	A-II
Quantitative culturing from the interior surface of the catheter, vortex and ultrasound treatment of the catheter to disengage adhesive bacteria	A-II
Endoluminal brushing if blood cultures cannot be drawn via CVC line	C-II
Ultrasound imaging along the catheter tunnel for diagnosis of CRI	C-III
Blood cultures from all lumina of the catheter	C-III
No cultures from the catheter hub	D-II
No skin swab for diagnosis of CRI	D-II
No placing of the catheter tip in broth and subsequently culturing the pathogen	E-II

Legend:

<sup>1</sup> DTTP (Differential Time To Positivity) – Difference in time between positivity of results of catheter culture and peripheral blood culture;

## 4 Therapy

First goal is the successful treatment of CRI using systemic antimicrobial therapy. Second goal is the prevention of secondary infection.

### 4.1 Antimicrobial Therapy

Recommendations are summarized in [Table 5](#).

**Table 5: Antimicrobial Therapy in CRI**

Recommendation	Category of Evidence
Antimicrobial treatment of suspected CRI based on the same principles as treatment of fever of unknown origin (FUO)	
Prompt empirical vancomycin therapy is not required	A-II
At least 2 weeks of systemic antimicrobial treatment in immunosuppressed patients	B-III
For <i>in vitro</i> susceptible pathogens, therapy with a penicillinase-resistant penicillin is more effective and, therefore, preferable to treatment with glycopeptide antibiotics	B-II
Antibiotic lock in addition to systemic antibiotic therapy has shown to reduce the relapse rate of CRI	C-III

### 4.2 Management of CVC

Recommendations are summarized in [Table 6](#).

**Table 6: Management of CVC**

Recommendation	Category of Evidence
Primary catheter removal is necessary in <ul style="list-style-type: none"> <li>• CRI due to <i>Staphylococcus aureus</i></li> <li>• CRI due to <i>Candida</i> spp.</li> <li>• Tunnel or pocket infection</li> <li>• Complicated CRI (e.g. metastatic organ or severe soft tissue infections)</li> </ul>	A-II B-II B-III B-II
Preservation of CVC may be initially attempted in clinically stable patients in the presence of the following pathogens <ul style="list-style-type: none"> <li>• Coagulase-negative Staphylococci</li> <li>• <i>Corynebacterium jeikeium</i></li> <li>• <i>Acinetobacter baumannii</i></li> <li>• <i>Stenotrophomonas maltophilia</i></li> <li>• <i>Pseudomonas aeruginosa</i></li> <li>• <i>Bacillus</i> spp.</li> </ul>	B-III

## 5 References

1. Wolf H. H. al.: Central venous catheter-related infections in hematology and oncology. Ann Hematol 2008;87:863-876. DOI:10.1007/s00277-008-0509-5

## 7 Links

<https://www.agiho.de/ueber-die-agiho>

## 8 Authors' Affiliations

### **Dr. med. Hans-Heinrich Wolf**

Südharzkrlinikum  
 Klinik für Innere Medizin III  
 Hämatologie, Onkologie, Hämostaseologie  
 Dr.-Robert-Koch-Str. 39  
 99734 Nordhausen  
[Hans.Wolf@shk-ndh.de](mailto:Hans.Wolf@shk-ndh.de)

### **Dr. med. Malte Leithäuser**

Gemeinschaftspraxis  
 Lakner/Decker/Leithäuser  
 Wismarische Str. 32  
 18057 Rostock  
[mleith@gmx.de](mailto:mleith@gmx.de)

### **Prof. Dr. med. Georg Maschmeyer**

Klinikum Ernst von Bergmann  
 Zentrum für Innere Medizin  
 Klinik für Hämatologie, Onkologie  
 und Palliativmedizin  
 Charlottenstr. 72  
 14467 Potsdam  
[georg.maschmeyer@klinikum-evb.de](mailto:georg.maschmeyer@klinikum-evb.de)

**Dr. med. Hans-Jürgen Salwender**

Asklepios Klinik Hamburg-Altona  
II. Medizinische Abteilung  
Hämatologie / Stammzelltransplantation  
Paul-Ehrlich-Str. 1  
22763 Hamburg  
[h.salwender@asklepios.com](mailto:h.salwender@asklepios.com)

**Dr. med. Ulrike Klein**

Universitätsklinikum Heidelberg  
Kaufmännische Leitung UFHK und ZKJM  
Im Neuenheimer Feld 430  
69120 Heidelberg  
[Ulrike.Klein2@med.uni-heidelberg.de](mailto:Ulrike.Klein2@med.uni-heidelberg.de)

**Prof. Dr. med. Iris Chaberny**

Universitätsklinikum Leipzig AöR  
Institut für Hygiene /  
Krankenhaushygiene  
Johannesallee 34, Haus L  
04103 Leipzig  
[Iris.Chaberny@medizin.uni-leipzig.de](mailto:Iris.Chaberny@medizin.uni-leipzig.de)

**Prof. Dr. med. Florian Weißinger**

Evangelisches Klinikum Bethel gGmbH  
Johannesstift  
Klinik für Innere Medizin, Hämatologie/Onkologie  
und Palliativmedizin  
Schildescher Str. 99  
33611 Bielefeld  
[florian.weissinger@evkb.de](mailto:florian.weissinger@evkb.de)

**Prof. Dr. med. Dieter Buchheidt**

Klinikum Mannheim GmbH  
Medizinische Fakultät Mannheim  
III. Medizinische Klinik  
Theodor-Kutzer-Ufer 1-3  
68167 Mannheim  
[dieter.buchheidt@umm.de](mailto:dieter.buchheidt@umm.de)

**Prof. Dr. med. Markus Ruhnke**

Helios Klinikum Aue  
Klinik für Hämatologie/Onkologie  
und Palliativmedizin  
Gartenstr. 6  
08280 Aue  
[Markus.Ruhnke@helios-gesundheit.de](mailto:Markus.Ruhnke@helios-gesundheit.de)

**Prof. Dr. med. Gerlinde Egerer**

Universitätsklinikum Heidelberg  
Medizinische Klinik V  
Hämatologie/Onkologie  
Im Neuenheimer Feld 410  
69120 Heidelberg  
[gerlinde.egerer@med.uni-heidelberg.de](mailto:gerlinde.egerer@med.uni-heidelberg.de)



**Prof. Dr. med. Oliver A. Cornely**

Uniklinik Köln, Klinik I für Innere Med.  
Zentrum für Klinische Studien  
Infektiologie-Hämatologie-Onkologie  
Kerpener Str. 62  
50937 Köln  
[oliver.cornely@uk-koeln.de](mailto:oliver.cornely@uk-koeln.de)

**Prof. Dr. med. Gerd Fätkenheuer**

Universität zu Köln  
I. Medizinische Klinik  
Joseph-Stelzmann-Str. 9  
50924 Köln  
[G.Faetkenheuer@uni-koeln.de](mailto:G.Faetkenheuer@uni-koeln.de)

**Dr. Sabine Mousset**

St. Josefs Hospital  
Medizinische Klinik III  
Palliativmedizin / Onkologie  
Beethovenstr. 20  
65189 Wiesbaden  
[smousset@joho.de](mailto:smousset@joho.de)

## **9 Disclosure**

according to the rules of the German Association of Hematology and Oncology (DGHO, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie) and the recommendations of the AWMF (version dated April 23, 2010) and international recommendations.